Securities Code: 002332 Securities Abbreviation: Xianju Pharmaceutical Announcement No.: 2026-012 Zhejiang Xianju Pharmaceutical Co., Ltd. Announcement on Continuing to Carry Out Foreign Exchange Hedging Business
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or major omissions.
Zhejiang Xianju Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the second meeting of the Ninth Board of Directors on April 21, 2026, and reviewed and approved the "Proposal on Continuing to Carry Out Foreign Exchange Hedging Business." The Company agreed to carry out foreign exchange hedging business with a cumulative amount at any point in time not exceeding USD 20 million or its equivalent in foreign currency within 12 months from the date of approval by this Board of Directors. The relevant situation is hereby announced as follows:
I. Purpose of the Company's Foreign Exchange Hedging Business
Since the export revenue from raw materials and related products accounts for a certain proportion of the Company's total operating revenue, and settlements are mainly made in foreign currencies such as US dollars and Euros, exchange rate fluctuations can have a certain impact on the Company's operating performance. To mitigate the impact of exchange rate fluctuations on the Company's profits, the Company plans to carry out foreign exchange hedging business with financial institutions such as banks, including forward foreign exchange settlement and sales transactions, foreign currency interest rate swaps, and RMB to foreign currency option combination transactions. By locking in forward foreign exchange settlement and sales rates and exchange rate ranges, the impact on the Company's operating profit will be reduced in the context of two-way fluctuations in the RMB to foreign currency exchange rate.